NCT07297212 2026-03-12
A Clinical Trial Testing the Safety of the Investigational Drug Pumitamig (BNT327) and How Well it Works in Patients With Recurrent Glioblastoma
BioNTech SE
Phase 2 Recruiting
Clinical Trials
79 trialsNCT02568267 2026-03-06
STARTRK-2
Hoffmann-La Roche
Phase 2 Active not recruiting
NCT01068782 2026-02-25
Multiple Doses and Regimens of Cabozantinib in Subjects With Grade IV Astrocytic Tumors in First or Second Relapse
Exelixis
Phase 2 Terminated
NCT07428616 2026-02-24
A Study of Zanzalintinib in Participants With Recurrent or Progressive Meningioma
Exelixis
Phase 2 Not yet recruiting
NCT06322342 2025-12-26
Phase 2 Ascending Dose Safety and Efficacy Study of RVP-001, a Manganese-based MRI Contrast Agent
Reveal Pharmaceuticals Inc.
Phase 2 Completed
NCT06777433 2025-11-24
RAD101
Radiopharm Theranostics, Ltd
Phase 2 Recruiting
NCT03050736 2025-09-04
Safety Study of VAL-083 and Radiotherapy in Patients With Newly Diagnosed GBM Having Unmethylated MGMT Expression
Kintara Therapeutics, Inc.
Phase 2 Completed
NCT02717962 2025-08-29
Study of VAL-083 in Patients With MGMT Unmethylated, Bevacizumab-naive Glioblastoma in the Adjuvant or Recurrent Setting
Kintara Therapeutics, Inc.
Phase 2 Completed
NCT04410367 2025-07-20
PURSUE
Blue Earth Diagnostics
Phase 2 Completed
NCT02986178 2025-07-11
Lerapolturev in Recurrent Malignant Glioma
Istari Oncology, Inc.
Phase 2 Completed
NCT03175224 2025-06-27
SPARTA
Apollomics Inc.
Phase 2 Recruiting
NCT04479241 2025-06-05
LUMINOS-101: Lerapolturev (PVSRIPO) and Pembrolizumab in Patients With Recurrent Glioblastoma
Istari Oncology, Inc.
Phase 2 Completed
NCT00538343 2025-05-29
RTA 744 in Breast Cancer Patients With Progression of Previously Irradiated Brain Metastases
Biogen
Phase 2 Terminated
NCT04762069 2025-05-04
A Study of Berubicin in Adult Subjects With Recurrent Glioblastoma Multiforme
CNS Pharmaceuticals, Inc.
Phase 2 Active not recruiting
NCT06161974 2025-02-21
Study of Olutasidenib and Temozolomide in HGG
Rigel Pharmaceuticals
Phase 2 Recruiting
NCT04824079 2025-01-22
Keynatinib in Treated Patients With NSCLC and Brain Metastases
Medolution Ltd.
Phase 2 Completed
NCT05146219 2024-12-30
Study of TY-9591 in Patients With a Lung Cancer With Brain or Leptomeningeal Metastases With EGFR Mutation
TYK Medicines, Inc
Phase 2 Completed
NCT05948813 2024-11-21
TY-9591 in the Patients With EGFR Mutations in Advanced NSCLC With Brain Metastases
TYK Medicines, Inc
Phase 2 Recruiting
NCT02014844 2024-05-29
Phase 2 Study to Investigate the Efficacy and Safety of Aldoxorubicin in Subjects With Glioblastoma
ImmunityBio, Inc.
Phase 2 Completed
NCT06374888 2024-04-19
Nilatinib Maleate Tablets Combined With Capecitabine in the Treatment of HER2-positive Advanced Esophageal/Esophagogastric Junction/Gastric Adenocarcinoma With Brain Metastases
Convalife (Shanghai) Co., Ltd.
Phase 2 Not yet recruiting
NCT03257631 2024-04-16
A Study of Pomalidomide Monotherapy for Children and Young Adults With Recurrent or Progressive Primary Brain Tumors
Celgene
Phase 2 Completed
NCT02614794 2023-08-14
HER2CLIMB
Seagen Inc.
Phase 2 Completed
NCT01290692 2023-07-03
Study To Test the Safety and Efficacy of TVI-Brain-1 As A Treatment for Recurrent Grade IV Glioma
TVAX Biomedical
Phase 2 Completed
NCT03911869 2023-05-31
POLARIS
Pfizer
Phase 2 Terminated
NCT01986348 2023-01-26
KING
Karyopharm Therapeutics Inc
Phase 2 Terminated
NCT00312728 2023-01-06
A Study of Bevacizumab in Combination With First- or Second-Line Therapy in Subjects With Treated Brain Metastases Due to Non-Squamous NSCLC (PASSPORT)
Genentech, Inc.
Phase 2 Completed
NCT03668847 2022-11-08
DM-CHOC-PEN for Brain Tumors in AYA Subjects
DEKK-TEC, Inc.
Phase 2 Completed
NCT02858895 2022-10-24
Convection-Enhanced Delivery (CED) of MDNA55 in Adults With Recurrent or Progressive Glioblastoma
Medicenna Therapeutics, Inc.
Phase 2 Completed
NCT05092802 2022-05-03
The Efficacy of HLX208 (BRAF V600E Inhibitor) for Refractory Primary Brain Tumors With BRAF Mutation After First-line Treatment
Shanghai Henlius Biotech
Phase 2 Unknown
NCT02000882 2022-02-07
STAR Cape+BKM120 MBC With Brain Met
US Oncology Research
Phase 2 Completed
NCT02844439 2021-09-22
Study of Tesevatinib Monotherapy in Patients With Recurrent Glioblastoma
Kadmon Corporation, LLC
Phase 2 Completed
NCT02798406 2021-07-15
CAPTIVE
DNAtrix, Inc.
Phase 2 Completed
NCT00219297 2021-02-21
Study of Patupilone in Patients With Brain Metastasis From Non-small Cell Lung Cancer
Novartis
Phase 2 Completed
NCT02038218 2020-09-16
DM-CHOC-PEN
DEKK-TEC, Inc.
Phase 2 Completed
NCT04415320 2020-06-04
X-396 (Ensartinib) Capsules in ALK-Positive NSCLC Patients With Brain Metastases
Betta Pharmaceuticals Co., Ltd.
Phase 2 Unknown
NCT02343406 2020-05-22
INTELLANCE-2
AbbVie
Phase 2 Completed
NCT02336451 2020-04-21
Ascend-7
Novartis
Phase 2 Completed
NCT00525590 2020-03-16
Exploratory Study, Evaluating the Treatment Effect of Surgery Plus GLIADEL® Wafer in Patients With Metastatic Brain Cancer
Eisai Inc.
Phase 2 Completed
NCT00062478 2020-03-12
Study of Karenitecin (BNP1350) in Patients With Brain Tumors
BioNumerik Pharmaceuticals, Inc.
Phase 2 Completed
NCT01967810 2020-02-25
ANG1005 in Patients With Recurrent High-Grade Glioma
Angiochem Inc
Phase 2 Completed
NCT02048059 2020-02-25
ANG1005 in Breast Cancer Patients With Recurrent Brain Metastases
Angiochem Inc
Phase 2 Completed
NCT01498328 2020-02-17
ReACT
Celldex Therapeutics
Phase 2 Completed
NCT00263588 2019-12-12
Lapatinib for Brain Metastases In ErbB2-Positive Breast Cancer
Novartis
Phase 2 Completed
NCT02039947 2019-05-21
Study to Evaluate Treatment of Dabrafenib Plus Trametinib in Subjects With BRAF Mutation-Positive Melanoma That Has Metastasized to the Brain
Novartis
Phase 2 Completed
NCT03916757 2019-04-17
GBM
Immunitor LLC
Phase 2 Unknown
NCT00093964 2019-04-16
Cilengitide (EMD 121974) for Recurrent Glioblastoma Multiforme (Brain Tumor)
EMD Serono
Phase 2 Completed
NCT02726568 2019-02-19
High Dose Icotinib With Sequential SRS For NSCLC Patients Harboring EGFR Mutation With Brain Metastases
Betta Pharmaceuticals Co., Ltd.
Phase 2 Unknown
NCT01497665 2019-01-22
GRABM-L
Angiochem Inc
Phase 2 Terminated
NCT03754530 2018-11-27
Icotinib Combined With Radiation Therapy For NSCLC Patients With Brain Metastases and EGFR Mutation
Betta Pharmaceuticals Co., Ltd.
Phase 2 Unknown
NCT01978236 2018-08-17
Dabrafenib/Trametinib, BRAF or BRAF AND MEK Pre-op With BRAF and MEK Post-op, Phase IIB, Melanoma With Brain Mets,Biomarkers and Metabolites
GlaxoSmithKline
Phase 2 Terminated